Amitriptyline
Amitriptyline is a tricyclic antidepressant primarily indicated for the management of major depressive disorder, particularly endogenous depression. It demonstrates significant efficacy in alleviating both the depressive symptoms and associated anxiety components common in clinical depression.
Clinical Overview
Primary Clinical Applications
Amitriptyline is most effective in treating moderate to severe depression, particularly with melancholic/endogenous features. Its sedative properties make it particularly valuable for patients presenting with significant anxiety alongside their depressive symptoms. The medication is not recommended for mild depressive states or situational depressive reactions.
Mechanism and Onset
As a tricyclic antidepressant, amitriptyline works by inhibiting the reuptake of norepinephrine and serotonin. While sedative effects typically appear rapidly, the full antidepressant response may take 3-4 days to 30 days to develop adequately, requiring patient counseling regarding delayed therapeutic onset.
Key Clinical Monitoring
Due to amitriptyline’s anticholinergic properties and cardiovascular effects, careful monitoring is essential, particularly in patients with cardiac disease, seizure history, or narrow-angle glaucoma. The drug carries significant drug interaction potential, especially with MAOIs, and requires careful consideration in patients receiving concurrent medications.
Key Clinical Points
Sedation arrives before antidepressant effect
Sedative effects appear rapidly while the antidepressant response may take up to thirty days to develop fully. Patients should be counselled on this gap, since early sedation without mood improvement is a common reason for discontinuation.
Boxed warning in patients under 25
Carries a boxed warning for increased suicidal thinking and behaviour in patients under 25 years. Closer monitoring is warranted during initiation and after dose changes in this age group.
Contraindicated after recent myocardial infarction
Should not be used during the acute recovery phase following myocardial infarction. ECG monitoring is indicated in any patient with existing cardiac disease, given the cardiotoxic potential of tricyclics.
MAOI washout of fourteen days
Concurrent use with an MAOI is contraindicated because of serotonin syndrome risk, and a minimum fourteen-day interval is required after stopping an MAOI before amitriptyline is started.
Anticholinergic burden limits use in older adults
Dry mouth, constipation, blurred vision, and urinary retention are common and are poorly tolerated in older patients. Starting doses of 10 to 25 mg at bedtime are recommended, with maintenance typically 25 to 50 mg daily.
Prescribing Information
Dosing & Administration
Adults – Outpatients:
- Initial: 25 mg three times daily or 75 mg at bedtime
- Maintenance: 50-100 mg daily (may increase to 150 mg daily if needed)
- Maximum: 300 mg daily for severely ill hospitalized patients
Elderly Patients:
- Initial: 10-25 mg at bedtime
- Maintenance: 25-50 mg daily
Indications
- Major depressive disorder in adults
- Off-label: Chronic pain, migraine prevention, insomnia, PTSD
Contraindications
- Recent myocardial infarction
- Concurrent MAOI use (within 14 days)
- Known hypersensitivity to tricyclic antidepressants
- Acute recovery phase following myocardial infarction
Warnings & Precautions
- Boxed Warning: Increased suicidal risk in patients under 25 years
- Cardiovascular effects: Monitor ECG in patients with cardiac disease
- Anticholinergic effects: Use caution in elderly patients
- Seizure risk: Lower seizure threshold
Drug Interactions
- MAOIs: Contraindicated – risk of serotonin syndrome
- CNS depressants: Enhanced sedation
- Anticholinergic drugs: Additive anticholinergic effects
- CYP2D6 inhibitors: Increased amitriptyline levels
Adverse Reactions
Common (>10%):
- Drowsiness, dizziness, dry mouth, constipation, blurred vision
Serious:
- Cardiac arrhythmias, seizures, anticholinergic toxicity
Special Populations
- Pregnancy: Category C – use only if benefits outweigh risks
- Renal Impairment: Dose adjustment may be necessary
- Hepatic Impairment: Use with caution, consider dose reduction
Frequently Asked Questions
What is Amitriptyline used for?
Amitriptyline is a tricyclic antidepressant primarily indicated for the management of major depressive disorder, particularly endogenous depression. It demonstrates significant efficacy in alleviating both the depressive symptoms and associated anxiety components common in clinical depression.
What class of drug is Amitriptyline?
Amitriptyline is classified as: Tricyclic Antidepressant.
Sedation arrives before antidepressant effect?
Sedative effects appear rapidly while the antidepressant response may take up to thirty days to develop fully. Patients should be counselled on this gap, since early sedation without mood improvement is a common reason for discontinuation.
Boxed warning in patients under 25?
Carries a boxed warning for increased suicidal thinking and behaviour in patients under 25 years. Closer monitoring is warranted during initiation and after dose changes in this age group.
Contraindicated after recent myocardial infarction?
Should not be used during the acute recovery phase following myocardial infarction. ECG monitoring is indicated in any patient with existing cardiac disease, given the cardiotoxic potential of tricyclics.
MAOI washout of fourteen days?
Concurrent use with an MAOI is contraindicated because of serotonin syndrome risk, and a minimum fourteen-day interval is required after stopping an MAOI before amitriptyline is started.
Source: FDA prescribing information (DailyMed)